We have entered a new era in understanding CNS circuitry involved in acute and chronic pain. The ability to objectively measure a pain or analgesic state of the brain using non-invasive methods that define neural activation provides the possibility for top-down approaches to drug discovery. These brain maps represent the specific brain state. In the future, correlations with such states and behavioral, genetic, epigenetic or other chemical markers may help define specific diagnostic tools and novel approaches to drug discovery.